Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

ND4BB: addressing the antimicrobial resistance crisis

The Innovative Medicines Initiative (IMI) recently launched its third public–private partnership, ENABLE (European Gram-negative Antibacterial Engine), to tackle the shortage of effective antimicrobial drugs for Gram-negative pathogens.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Boucher H. W. et al. Clin. Infect. Dis. 56, 1685–1694 (2013).

    Article  Google Scholar 

  2. 2

    Morel C. M. & Mossialos E. BMJ 340, c2115 (2010).

    Article  Google Scholar 

  3. 3

    Laxminarayan R. et al. Lancet Infect. Dis. 13, 1057–1098 (2013).

    Article  Google Scholar 

  4. 4

    Rex J. H. et al. Lancet Infect. Dis. 13, 269–275 (2013).

    Article  Google Scholar 

  5. 5

    Caliendo A. M. et al. Clin. Infect. Dis. 57, S139–S170 (2013).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to John H. Rex.

Ethics declarations

Competing interests

J.H.R. is an employee and shareholder of AstraZeneca Pharmaceuticals. He is a non-executive director of, shareholder of, and consultant to F2G Pharmaceuticals and a consultant to Advent Life Sciences (an investor in F2G Pharmaceuticals).

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rex, J. ND4BB: addressing the antimicrobial resistance crisis. Nat Rev Microbiol 12, 231–232 (2014).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing